Collaboration Will Simplify and Streamline Users' Ability to Find Personalized Care Delivered by Licensed Mental Health Clinicians PALO ALTO, Calif. and SCOTTSDALE, Ariz., Oct. 28, 2025 /PRNewswire/ -- Calm Health, Calm's evidence-based mental health app available through health plans, providers and employers, today announced it has partnered with LifeStance Health, one of the nation's largest providers of virtual and in-person...Read more
A customized program for YMCA of East Tennessee members will include educational series “Wisdom Wednesdays,” and access to Cardio Diagnostics’ AI-powered cardiovascular testing at discounted rates from home or during the Heart Health Fair KNOXVILLE, Tenn. & CHICAGO / Oct 28, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the...Read more
SANTA CLARA, Calif. / Oct 28, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a partnership with HeartNexus, Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer-to-peer consultations, and on-demand telemedicine visits. “Working with HeartNexus accelerates our...Read more
CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution...Read more
The new Saudi-based CoMira Diagnostics joint venture will be engaged in manufacturing and distribution of the Company's upcoming Co-Dx™ PCR platform and other Co-Dx IP across KSA and 18 other MENA countries SALT LAKE CITY, Oct. 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...Read more
MIDDLETON, Wis. and SARASOTA, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced a strategic partnership with Heidi Health to integrate its innovative AI-powered scribe...Read more
Strategic partnership will link DNA data with rich clinical data to identify novel biomarkers for targeted cancer therapies The two companies will utilize AI and multimodal molecular data to unlock new insights for personalized oncology treatments PALO ALTO, Calif. & MCLEAN, Va. / Oct 27, 2025 / Business Wire / Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine...Read more
Collaboration underscores both companies’ commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery technologies WILMINGTON, Del. & CINCINNATI / Oct 27, 2025 / Business Wire / Incyte (NASDAQ:INCY) and Enable Injections, Inc. (“Enable”) today announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational,...Read more
The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage biotechnology company...Read more
The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by...Read more
MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”) Plasmid DNA technology platform. This new agreement builds and expands on the existing successful partnership between the two companies, which has...Read more
Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo CAR therapies for autoimmune diseases BOSTON, Oct. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) Engineering of Immune Cell Inside the Body...Read more
Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an expansion of their partnership to bolster clinical research. This new agreement will...Read more
RA'ANANA, Israel, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic collaboration with Bites Learning Ltd. (“Bites”), a leader in AI-based digital training and performance enablement solutions. Through this collaboration, Bites’ advanced AI-powered...Read more
WILMINGTON, Mass. / Oct 22, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies. This agreement leverages an integrated approach to streamline discovery and...Read more
Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage Program Takeda to Lead IBI363 Global Co-Development and U.S. Co-Commercialization and Will Have Exclusive Commercialization Rights Outside the U.S. and Greater China; IBI363 is a Late-Stage Bispecific Antibody Fusion Protein Being Evaluated in...Read more
PASADENA, Calif. / Oct 21, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Summary of...Read more
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel...Read more
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024 Partnership brings together both companies’ expertise in biosimilars TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical...Read more
Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applications to follow - making advanced analysis more accessible to the broader researcher community PLEASANTON, Calif., Oct. 20, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and Anthropic, an AI safety and research company and creator of Claude, today...Read more
Queen’s and a nationally recognized academic medical center to provide clinical expertise to enhance GE HealthCare’s forthcoming software solution New software solution will use AI and predictive analytics to recommend actions and help care teams improve quality of care, patient flow, and maximize resources CHICAGO / Oct 20, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced collaborations with two leading U.S. health...Read more
X-Chem’s DNA-encoded library complements Charles River’s discovery expertise to accelerate hit identification WILMINGTON, Mass. / Oct 20, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and...Read more
TOKYO & HAYWARD, Calif. / Oct 19, 2025 / Business Wire / Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain other territories in Asia...Read more
Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product sales for the first license agreement Chugai has the option to extend its rights to partner with Rani on up to 5 additional drug targets at similar deal terms bringing the total potential deal value to over $1...Read more
ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO a strategic agreement to bring cutting-edge liquid biopsy genomic testing to the Japanese population. The companies will also partner to commercialize a liquid biopsy companion...Read more
EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy CRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has finalized an exclusive agreement with EVERSANA®, a...Read more
CHICAGO / Oct 16, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to...Read more
Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck® LAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company with a focus in life-saving medical solutions today announced that the company has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck®, a...Read more
Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Conditions Samsung C&T Will Drive Commercialization of Galleri in South Korea With Possible Expansion to Japan and Singapore Samsung Electronics and GRAIL Will Also Explore Potential Strategic and Operational Collaborations SEOUL, Korea and MENLO PARK, Calif., Oct. 16, 2025 /PRNewswire/ -- Samsung C&T...Read more
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases DNTH212 has the potential to...Read more
CHICAGO, Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced a Collaboration and License Agreement with Sanofi, an R&D driven, AI-powered biopharma company, committed to improving people's lives and delivering compelling growth. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY EVOQ's...Read more
APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, to help identify novel biomarkers that enable earlier detection and more precise...Read more
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments, up to a total of 2.1 billion dollars including potential development and commercial milestones, plus tiered royalties on net sales Bagsværd, Denmark and Seattle, US, 15 October 2025 – Novo...Read more
AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials LA JOLLA, Calif., Oct. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic...Read more
Florida Institute for Pediatric Rare Diseases and Representative Adam Anderson ushering in a new era of preventative care with support from GeneDx’s comprehensive genomic testing and sequencing solutions GAITHERSBURG, Md. / Oct 13, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Florida State University has selected GeneDx as one of its partners for...Read more
ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced they have entered into a Collaboration Agreement to advance robotic Pulsed Field Ablation (PFA) technology towards...Read more
TEANECK, N.J. / Oct 09, 2025 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset targeting periodontal health in companion animals. This agreement grants Phibro exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma’s proprietary...Read more
Partnership has successfully completed analytical validation of a cheek swab collection solution for testing and identifying patients with the genotypes important for AD04 development GLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and...Read more
Brands Will Donate One Pack of Opill® to NY Birth Control Access Project for Each Opill®-Themed Chill Tips Set Sold GRAND RAPIDS, Mich., Oct. 9, 2025 /PRNewswire/ -- Today, Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced that Opill® — the first and only daily birth control pill available without a prescription in the U.S. —is partnering with self-care brand Chillhouse to...Read more
Jaguar Gene Therapy joins as founding partner to initiate a genetic testing program for SHANK3-related autism spectrum disorder and Phelan-McDermid syndrome GAITHERSBURG, Md. / Oct 09, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the Autism Partnership Program to expand access to its industry leading exome and genome testing – the only autism...Read more
Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit Establishes a framework to define and propose future portfolios Extends collaboration through 2032, reinforcing Bio-Techne's diagnostics growth strategy and strengthening relationship with Oxford Nanopore Technologies MINNEAPOLIS, Oct. 9, 2025 /PRNewswire/ -- Bio-Techne...Read more
MCLEAN, Va. & DUBAI, United Arab Emirates / Oct 08, 2025 / Business Wire / Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, and iO Health-FZE, an innovator in AI-driven healthcare technology, today announced a strategic agreement aimed at delivering Optima AI across the Middle East and North Africa...Read more
Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent’s preclinical study results provide proof-of-concept support for leveraging certepetide-related biology through its use as an ADC payload BASKING RIDGE, N.J. and TAMPA, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”...Read more
WILMINGTON, Mass. / Oct 08, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Toxys today announced a collaboration that offers Charles River’s clients access to ReproTracker®, a state-of-the-art human stem cell-based in vitro assay that rapidly and reliably identifies developmental toxicity hazards of new drugs and chemicals. As leveraged in the use of developmental and reproductive toxicology (DART)...Read more
FRANKLIN LAKES, N.J., Oct. 8, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for accessible lab automation with more than 10,000 robotic systems deployed, today announced a multi-year collaboration. Together, BD and Opentrons will integrate robotic liquid-handling capabilities into BD single-cell multiomics instruments,...Read more
Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple Sclerosis (MS) - Pivotal Phase 3 clinical trial evaluating orelabrutinib in patients with Primary Progressive MS (PPMS) initiated; Pivotal Phase 3 clinical trial in patients with Secondary Progressive MS (SPMS) expected to initiate in 1Q...Read more
Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing MENLO PARK, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced an expanded partnership with seqWell, a global provider of genomic library and...Read more
SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized compound, NDL2, is an advanced PD-L1 protein degrader currently in development and represents a new and innovative frontier of cancer...Read more
Clinical-Stage Biotechnology Company Leverages Artificial Intelligence SARASOTA, Fla. / Oct 07, 2025 / Business Wire / Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded...Read more
MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapies ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a...Read more
Launch of End-to-End Workflow for AVITI and AVITI24™ Enabling Sample to Sequencer in as Little as Five Hours Twist Gains Exclusive Access to the new, co-developed Trinity Freestyle™ Sequencing Workflow SOUTH SAN FRANCISCO, Calif. & SAN DIEGO / Oct 06, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, and Element Biosciences, Inc., a company democratizing...Read more
Collaboration designed to drive measurable return on investment ("ROI") for health plans by reducing falls and improving outcomes for high-risk populations, including those with obesity and Medicare Advantage members with frailty and balance issues Generating more than $50 billion annually in direct medical costs, falls are one of the leading causes of injury among older adults in the U.S. NEW YORK, Oct. 6, 2025 /PRNewswire/...Read more
Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening WALTHAM, Mass. / Oct 02, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (EURONEXT: SAN and NASDAQ: SNY). Revvity will develop a T1D 4-plex in...Read more
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific...Read more
APOLLO BEACH, Fla. and HUNTINGTON, W.Va., Oct. 01, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, and RGEN Inc., a leader in genetic research and innovation (“RGEN”), today...Read more
GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M® adjuvant. The companies have amended their CLA to expand Sanofi's license to include use of Novavax's Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program. Sanofi recently received funding...Read more
TAMPA, FL / ACCESS Newswire / September 30, 2025 / Wellgistics Health, Inc. ("Wellgistics Health" or the "Company") (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced a strategic collaboration with TheracosBio, the manufacturer of Brenzavvy® (bexagliflozin), to make diabetes medications more affordable and accessible across the U.S....Read more
Ozempic® is now available at this reduced price to eligible self-pay LifeMD patients NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk that provides access to Ozempic® (semaglutide), a GLP-1 RA for patients with type 2 diabetes, at $499 per month. Through LifeMD’s integration with...Read more
MADISON, Wis., Sept. 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced today the signing of a memorandum of understanding (MOU) to advance online adaptive radiotherapy (OART) on the Accuray helical radiation treatment delivery platform. As part of the MOU, the two parties outlined their intent to collaborate on clinical research, education...Read more
Labcorp to leverage Roche's digital pathology technology to expand access, enhance efficiency and support AI integration across anatomic pathology services BURLINGTON, N.C., Sept. 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today a collaboration with Roche to implement the company's FDA-cleared VENTANA® DP 600 and DP 200 slide scanners. The investment...Read more
CERRITOS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), a pioneer in value-based community oncology care, is pleased to announce a new partnership with Protocol Behavioral Health, a leading provider of evidence-based mental health care for cancer patients. This collaboration underscores TOI’s commitment to delivering whole-person care by integrating behavioral health services directly into the cancer...Read more
TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has signed a distribution agreement with Veridion Group (“Veridion”) of New Zealand, to act as exclusive distribution agent for its LaNeo MDMA...Read more
Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with...Read more
MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway to first half of 2027 MSD will assume full responsibility for the further development of EVX-B3 with Evaxion eligible for development, regulatory and sales milestone payments with a potential value of up to $592 million, as well as royalties on sales MSD retains an option for a second vaccine candidate,...Read more
MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced a strategic partnership with Medcase, a worldwide network of healthcare professionals focused on medical data annotation. This collaboration establishes a new market entry point for OneMedNet and opens a high-growth revenue channel in the healthcare...Read more
Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network PALO ALTO, Calif. & SECAUCUS, N.J. / Sep 24, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant’s...Read more
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus’ piflufolastat F18 (PYLARIFY® in U.S. market) in Japan for prostate cancer diagnostics and companion diagnostic use. PYLARIFY is used for positron emission tomography (PET)...Read more
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage...Read more
New program delivers TULSA Procedure’s precision treatment - minimal side effects, no overnight hospital stay – to Medicare patients across Texas TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company developing AI-powered, incision-free therapies for ablating diseased tissue, announced today the launch of a first-of-its-kind...Read more
Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy Solid to receive an upfront payment and is eligible for certain development and sales milestones and tiered royalties on net sales Solid continues to expand collaborative efforts for AAV-SLB101 with more than 25 agreements and licenses...Read more
With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the customer experience for health systems, hospitals, independent providers and their patients SECAUCUS, N.J., Sept. 23, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for healthcare providers and patients...Read more
Hangzhou, China, Sept. 22, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. (“Work Hangzhou”) and its subsidiaries in China, today announced the signing of a strategic cooperation agreement (the “Agreement”) between Work Hangzhou and the Wuxi Branch of Ruijin...Read more
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a new collaboration focused on glioblastoma (GBM) research. The collaboration, supported by a license to proprietary know-how,...Read more
SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung...Read more
CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG (“Proteomedix”) has signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics...Read more
BOSTON, Sept. 22, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages...Read more
Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development of novel gene editing therapies WALTHAM, Mass. / Sep 22, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity’s established Pin-pointTM base editing platform. The result is...Read more
GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients Second investigator-initiated trial to evaluate efti in earlier stage disease where its unique activation of a broad anti-cancer immune response may drive optimal benefit and high pathologic response rates SYDNEY, AUSTRALIA, Sept. 22, 2025 (GLOBE NEWSWIRE)...Read more
FRANKLIN LAKES, N.J., Sept. 22, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a pharmacy automation partnership with Henry Ford Health to develop the health system pharmacy of the future, with an initial focus on a robotic solution that will enable patients to pick up select prescriptions at their convenience — 24 hours a day, seven days a...Read more
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discuss strategic collaboration at upcoming Italian Society for Organ and Tissue Transplantation...Read more
Implementation will enable users to purchase, schedule appointments for testing, and receive results of lab tests performed by Quest within the WHOOP app, supporting access to deeper health and performance insights. BOSTON / Sep 18, 2025 / Business Wire / WHOOP, the human performance company, today announced that Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will be the U.S. lab provider for...Read more
ALAMEDA, Calif. / Sep 18, 2025 / Business Wire / Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced a research collaboration agreement with Immunome, Inc. (NASDAQ: IMNM) for the discovery and optimization of novel antibodies. Under the agreement, Immunome will receive target exclusivity. Financial terms of the deal were not disclosed. Infinimmune rapidly optimizes and engineers early...Read more
Collaboration spans workers' compensation, nursing homes, and outpatient clinics PETACH TIKVA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration between its U.S. subsidiary Nanox Impact Inc. and Monarch Medical Management and Billing LLC (“Monarch”), an experienced healthcare management organization...Read more
SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will utilize Adagene’s SAFEbody technology platform to generate a masked monoclonal antibody from the company’s pipeline for the development of an antibody-drug conjugate (ADC) against an...Read more
NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Sharps Technology ("Sharps Technology" or the "Company") (NASDAQ: STSS), a medical device company with a Solana digital asset treasury, and BONK, one of the premier community-driven platforms of the Solana ecosystem, today announced a strategic partnership to leverage BONK's liquid staking infrastructure as part of STSS's treasury strategy. As part of this initiative, STSS intends to stake a...Read more
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ: TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its...Read more
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s growing preclinical immunology portfolio Monte Rosa to receive an upfront payment of $120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered royalties on global net sales...Read more
Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases,...Read more
Multi-Year Partnership Renewal with Broadened Focus Will Include Expedited Technology Adoption and Market-Based Strategic Development of Next-Generation Monitoring Solutions IRVINE, Calif. / Sep 11, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced a multi-year renewal and expansion of its strategic partnership with Royal Philips (NYSE: PHG, AEX: PHIA). Building on over two decades of collaboration, this significant...Read more
WILMINGTON, Mass. / Sep 11, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) has recently announced two strategic collaborations across its contract development and manufacturing organization (CDMO), aimed at advancing novel oncology research and development. These collaborations include forming an alliance with the Parker Institute for Cancer Immunotherapy and supporting a streamlined manufacturing process...Read more
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE